Associations between Prediagnostic Circulating Bilirubin Levels and Risk of Gastrointestinal Cancers in the UK Biobank

Nazlisadat Seyed Khoei 1*, Karl-Heinz Wagner 1†, Robert Carreras-Torres 2†, Marc J. Gunter 3, Neil Murphy 3,∗,† and Heinz Freisling 3,∗,†

1 Department of Nutritional Sciences, Faculty of Life Sciences, University of Vienna, Althanstrasse 1, 1090 Vienna, Austria; nazlisadat.seyedkhoei@univie.ac.at (N.S.K.); karl-heinz.wagner@univie.ac.at (K.-H.W.)
2 Colorectal Cancer Group, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), Avinguda de la Granvia de l’Hospitalet 199-203, L’Hospitalet de Llobregat, 08908 Barcelona, Spain; carreras@idibell.cat
3 Nutrition and Metabolism Branch, International Agency for Research on Cancer (IARC-WHO), 150 Cours Albert Thomas, CEDEX 08, 69372 Lyon, France; gunterm@iarc.fr

* Correspondence: murphyn@iarc.fr (N.M.); Freislingh@iarc.fr (H.F.)
† These authors contributed equally to this work, Shared last authorship.

Simple Summary: Evidence from experimental studies suggests that bilirubin, a metabolic by-product of hemoglobin breakdown, has anticancer activity and may, therefore, reduce the risk of gastrointestinal (GI) cancers. We conducted a prospective study among 440,948 participants in the UK Biobank and found that higher prediagnostic circulating bilirubin levels were robustly associated with a lower risk of developing esophageal adenocarcinoma, which is compatible with the antioxidant hypothesis of bilirubin. We further observed negative associations between bilirubin and risk of colorectal cancer, which were less robust and could be due to reverse causality, whereby undiagnosed cancer affects bilirubin levels. The observed positive associations between bilirubin and risk of hepatobiliary cancers may indicate underlying liver disease processes. No associations were found for cancers of the mouth, stomach, and pancreas. Bilirubin is a novel biomarker for disease development that is routinely measured in clinical settings. Provided that our findings are replicated in further studies, circulating bilirubin could serve as a future risk stratification marker for certain GI cancers.

Abstract: We investigated associations between serum levels of bilirubin, an endogenous antioxidant, and gastrointestinal cancer risk. In the UK Biobank, prediagnostic serum levels of total bilirubin were measured in blood samples collected from 440,948 participants. In multivariable-adjusted Cox proportional hazard regression, we estimated hazard ratios (HR) and 95% confidence intervals (CI) for associations between bilirubin levels and gastrointestinal cancer risk (colorectum, esophagus, stomach, mouth, pancreas, and liver). After a median follow-up of 7.1 years (interquartile range: 1.4), 5033 incident gastrointestinal cancer cases were recorded. In multivariable-adjusted models, bilirubin levels were negatively associated with risk of esophageal adenocarcinoma (EAC, HR per 1-SD increment in log-total bilirubin levels 0.72, 95%CI 0.56–0.92, p = 0.01). Weak and less robust negative associations were observed for colorectal cancer (CRC, HR per 1-SD increment in log-total bilirubin levels 0.95, 95%CI 0.88–1.02, p = 0.14). Bilirubin levels were positively associated with risk of hepatocellular carcinoma (HCC, HR per 1-SD increment in log-total bilirubin levels 2.07, 95%CI 1.15–3.73, p = 0.02) and intrahepatic bile duct (IBD) cancer (HR per 1-SD increment 1.67, 95%CI 1.07–2.62, p = 0.03). We found no associations with risks of stomach, oral, and pancreatic cancers.

Prediagnostic serum levels of bilirubin were negatively associated with risk of EAC and positively associated with HCC and IBD cancer. Further studies are warranted to replicate our findings for specific GI cancers.

Keywords: gastrointestinal cancers; cancer risk; bilirubin; UK Biobank
1. Introduction

Gastrointestinal (GI) cancers are among the most common malignancies worldwide and contributed to approximately 26% of incident cancers and 35% of cancer-related deaths in 2018 [? ]. With the possible exception of gastric non-cardia cancer, where incidence and mortality rates have been declining, incidence of esophageal adenocarcinoma (EAC), and cancers of the gastric cardia, colorectum, liver and pancreas are projected to increase globally. Primary prevention and early detection measures will be critical to reduce the global burden of these cancers [? ].

The GI tract is highly exposed to reactive oxygen species (ROS) from external and internal sources, such as from cigarette smoke, alcohol consumption, viral/bacterial infections, or inflammatory disorders [? ]. An imbalance between ROS and antioxidants can lead to oxidative-stress-induced damage to DNA, which is one of the major pathways that can lead to cancer development [? ].

Antioxidants are compounds that can protect against oxidative stress, which is why the antioxidant prevention of GI cancers has drawn considerable attention [? ]. Humans ingest exogenous antioxidants from foods, but also possess a variety of endogenous antioxidant compounds that may prevent oxidative damage [? ]. Serum bilirubin, a byproduct of hemoglobin breakdown, has been shown to have potent endogenous antioxidant properties [? ? ? ? ]. Bilirubin has an inhibitory impact on nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity, which explains much of the profound antioxidant property of heme oxygenase-1 (HO-1). HO-1 is the key enzyme in heme degradation to biliverdin, the latter being converted into bilirubin [? ]. Congenital under-expression of hepatic uridine-diphosphoglucuronate glucuronosyltransferase1A1 (UGT1A1) causes mild chronic unconjugated hyperbilirubinemia, known as Gilbert’s syndrome (GS). Individuals with GS have mildly raised total bilirubin levels in the blood (≥17.1 µM/L) with normal serum activities of liver transaminases, biliary damage markers, and red blood cell counts [? ]. Under physiologic conditions, total bilirubin is the summation of indirect (~80 to 85%) and direct (~15 to 20%) bilirubin [? ]. The GS polymorphism is present in 10% of Europeans and 25% of individuals of African descent, although not all are exhibiting the phenotypic expression as overt hyperbilirubinemia (≥17.1 µM/L) [? ? ? ].

Bilirubin may be particularly relevant in GI cancer development given that UGT1A1 is highly expressed in GI tissues [? ] and that the liver, bile ducts, colon and rectum, and pancreas are important organs in metabolizing and excreting bilirubin [? ]. Findings from our previous in vitro studies supported anti-mutagenic effects of bilirubin, which may be particularly relevant for gut health. Intestinally cyclic tetrapyroles, which are part of the bile pigment family, prevented genotoxicity induced by heterocyclic amines (HCAs) and resulted in apoptotic death in cancer cells [? ? ? ]. However, the hypothesis that higher circulating bilirubin levels, which are indicative of bilirubin metabolism, are related to GI cancer risk is understudied. The few prospective studies investigating circulating bilirubin associated with colorectal cancer (CRC) and hepatocellular carcinoma (HCC) reported inconsistent results [? ? ? ]. The genetically predicted high activity of UGT1A1, indicative of lower levels of circulating bilirubin, was positively associated with risk of esophageal squamous cell carcinoma (ESCC) [? ], and not associated with risk of oral cancer [? ]. Jiraskova et al. [? ] reported a negative association between the UGT1A1*28 polymorphism (presence of 7 TA repeats in the promoter region of the gene) and CRC risk in men; however, a positive association was reported in a Macedonian retrospective case-control study in men [? ]. We are not aware of other studies investigating circulating levels of bilirubin associated with risks of esophageal, stomach, oral or pancreatic cancers.

We investigated associations between pre-diagnostic circulating total bilirubin levels and risk of GI cancers (colorectum, esophagus, stomach, mouth, pancreas, and liver) in the UK Biobank (UKB) study, a large prospective cohort including >500,000 participants.
2. Methods

2.1. Study Population

The UKB is a large, population-based prospective cohort study which is designed to provide data on the lifestyle, genetic, and environmental factors of important diseases [1]. This research has been conducted using the UKB Resource under application number 25897. Between 2006 and 2010, over 500,000 individuals (54% women) aged 40–69 years were recruited from one of 22 study centers across the UK (England, Wales, and Scotland). Approximately 9.2 million people were invited by the UKB to participate in this study through postal invitation with a telephone follow-up (response rate: 5.7%). All participants were registered with the UK National Health Service (NHS) and lived within 40 km of one of those 22 centers. The UKB has approval from the North West Multi-centre Research Ethics Committee, the National Information Governance Board for Health and Social Care in England and Wales, and the Community Health Index Advisory Group in Scotland. In addition, an independent Ethics and Governance Council was formed in 2004 to oversee UK Biobank’s continuous adherence to the Ethics and Governance Framework that was developed for the study (http://www.ukbiobank.ac.uk/ethics/, accessed on 3 July 2019). All participants provided written informed consent.

At the baseline assessment, participants completed a touchscreen self-reported questionnaire providing information on socio-demographics (age, sex, education, and Townsend deprivation index), health and medical history (vasectomy, hypertension, and diabetes), and lifestyle exposures (including smoking status, diet, physical activity, and alcohol consumption). Participants underwent anthropometric measurements, including body weight, height, and waist and hip circumference. Blood samples were collected, labeled, centrifuged, and stored at $-80^\circ C$ from all participants at recruitment and also from a subset of ~20,000 participants who re-attended the study center for a repeat assessment visit between 2012 and 2013.

Exclusions prior to the onset of analyses were participants with prevalent cancer at recruitment ($n = 27,264$) and participants without a total bilirubin measurement ($n = 31,373$). The final analytical cohort consisted of 440,948 participants.

2.2. Blood Collection and Laboratory Methods

As part of the UKB Biomarker Project, serum levels of total bilirubin and direct bilirubin were determined by a colorimetric assay (Beckman Coulter United Kingdom Ltd., Beckman Coulter AU5800 analyzer). Information on assay performance and the Coefficients of Variation (CVs) have been published [2]. The average within-laboratory CV for low, medium, and high internal quality control level samples for total and direct bilirubin ranged from 1.48 to 1.92% and 1.73 to 2.60%, respectively. A total of 15,611 participants had total bilirubin levels measured in blood samples collected at both the recruitment and repeat assessment visit (median of 4 years apart).

2.3. Follow-Up and Outcomes

Incident cancer cases and cancer cases recorded first in death certificates within the UKB cohort were identified through linkage to national cancer and death registries. Prevalent cancer cases were identified by linkage to cancer registries. Participants were followed from their baseline visit until the end of October 2015 for Scotland and the end of March 2016 for England and Wales.

Cancer incidence data were coded using the 10th Revision of the International Classification of Diseases (ICD-10). Separate analyses were conducted for colorectal (C18–C20), esophageal (C15), oral (C04), stomach (C16), liver (C22), and pancreatic (C25) cancers.

CRC cases were classified by location (anatomical sub-site), as cancers of colon (C18) and rectum (C19–C20). Cases of esophageal cancer were classified by histology, and these topography codes were combined with ICD-3 for oncology morphological codes [3] to further categorize esophageal cancer into adenocarcinoma (8140, 8144, 8145, 8260, 8480, 8481, 8490, and 8574) and ESCC (8070 and 8071). Stomach cancer was classified by
location (anatomical sub-site), where possible, as cancers of the stomach cardia (C16.0) and stomach non-cardia site (C16.1–16.5). Liver cancer cases were classified as HCC (C22.0) and intrahepatic bile duct (IBD, C22.1).

2.4. Statistical Analysis
To assess reproducibility between the two measurements of total bilirubin available in a subsample of participants, we calculated intra-class correlation coefficients (ICC) by dividing the between-person variance by the sum of the between- and within-person variances. Given that the two measurements of total bilirubin were a median of 4 years apart, the ICC reflects both technical and biological within-person variation.

Cox proportional hazards regression was used to estimate cause-specific hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between total bilirubin levels and incident cancers of the colorectum (colon and rectum), esophagus (EAC and ESCC), stomach (cardia and non-cardia), mouth, pancreas, and liver (HCC and IBD). The time variable in all models was age. Entry time was age at recruitment and exit time was age at whichever of the following came first: cancer diagnosis, death, or the last date at which follow-up was completed. All models were stratified by sex (except when models were run separately in men and women), age at recruitment in 5-year categories (<45, 45–49.9, 50–54.9, 55–59.9, 60–64.9, and ≥ 65 years), socio-economic status (Townsend deprivation index quintiles), and the recruitment centers.

Total bilirubin was modelled on a continuous scale (per 1-SD increment of log-total bilirubin levels) for men and women combined and by sex (except when number of events for a given cancer site was limited).

Based on prior knowledge and to avoid over-adjustment, we decided to control for confounding for each cancer separately by considering risk factors with strong evidence for each individual cancer. The multivariable models were adjusted for waist circumference (per 5 cm), smoking status and intensity (never, former, current- < 15/day, current- ≥ 15/day, current-intensity unknown, unknown), alcohol consumption frequency (never, special occasions only, 1–3 times/month, 1–2 times/week, 3–4 times/week, daily/almost daily, unknown), and qualifications (Certificates of secondary education/Ordinary-levels/General Certificates of Secondary Education or equivalent, National Vocational Qualification/Higher National Diploma/Higher National Certificate/Advanced-levels/Advanced Subsidiary-levels or equivalent, other professional qualifications, college/university degree, none of the above).

The HCC and IBD cancer models were further adjusted for total physical activity (<10, 10–19.9, 20–39.9, 40–59.9, ≥ 60 metabolic equivalent hours/week), and height (per 10 cm). The pancreatic cancer model was further adjusted for prevalent diabetes, and the CRC model was additionally adjusted for frequency of red/processed meat intake (<2, 2–2.99, 3–3.99, ≥ 4 occasions/week), family history of CRC (no/yes), total intake of fruits and vegetables (tablespoons/day), regular aspirin/ibuprofen use (no/yes), and if participants had ever had menopausal hormone therapy (no/yes).

Analyses were conducted by sex and anatomical sub-site/histology. The heterogeneity of associations by sex and across subsites was assessed by calculating log-likelihood ratio (LR). We also investigated potential non-linear dose–response associations between circulating levels of total bilirubin and GI cancer risk by applying cubic spline models combined with an LR test.

The associations between circulating total bilirubin and GI cancers were further assessed across subgroups of sex, median body mass index (BMI, 26.7 kg/m²), age at recruitment (50 years), and smoking status (never, former, and current). For these subgroup analyses, we used a more stringent p-value < 0.002 to correct for multiple testing (0.05 divided by the number of tests). In contrast, we did not adjust our main analysis for the six cancer outcomes for multiple testing given that our hypothesis was based on a strong prior hypothesis. In a sensitivity analyses, we excluded those participants with less than 2 years of follow-up to assess potential reverse causation. We report results...
for total bilirubin after adjusting for regression dilution by dividing the respective HRs (and 95%CIs) by the regression dilution ratio (RDR) value (=0.72). We also report results for direct and indirect bilirubin for the fully adjusted models. Last, we assessed the influence of high levels of circulating liver enzymes on our results by excluding participants in the highest decile of circulating alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), and gamma-glutamyl transpeptidase (GGT).

Analyses were conducted in Stata version 15.0 (Stata Corp, College Station, TX, USA). Statistical tests were all two-sided and a $p$-value < 0.05 was considered statistically significant.

3. Results

3.1. General Characteristics of the Study Population

During a median follow-up time of 7.1 years (interquartile range: 1.4), incident cases of the following GI cancers were recorded: 3002 colorectum (1989 colon and 1013 rectum), 338 esophageal adenocarcinoma, 124 esophageal squamous cell, 139 stomach cardia, 92 stomach non-cardia, 524 mouth, 559 pancreas, 135 hepatocellular, and 120 intrahepatic bile duct.

The characteristics of the study population by tertiles of total bilirubin levels are summarized in Table 1. Compared to the lowest tertile of total bilirubin, participants in the highest tertile had on average a lower waist circumference, were less likely to be current smokers, were less likely to have diabetes, and were more likely to have a college/university degree.

| Baseline Characteristic          | Colorectal cancer | Colon cancer | Rectal cancer | Esophageal adenocarcinoma | Esophageal squamous-cell carcinoma | Stomach cardia cancer | Stomach non-cardia cancer | Oral cancer | Pancreatic cancer | Hepatocellular carcinoma | Intrahepatic bile duct cancer | Age at recruitment (years) | Body mass index (kg/m²) | Waist circumference (cm) | Height (cm) |
|---------------------------------|-------------------|--------------|---------------|---------------------------|-----------------------------------|-----------------------|--------------------------|-------------|------------------|--------------------------|----------------------------|-------------------------|------------------------|--------------------------|--------------|
| Cases (N)                       | 614               | 370          | 244           | 124                       | 31                                | 41                    | 18                      | 126         | 110              | 15                       | 17                         | 56.3 (8.1)              | 28.2 (4.5)            | 97.9 (11.8)              | 174.9 (6.8)  |
| 1 (1.43–7.94)                   | 614               | 370          | 244           | 124                       | 31                                | 41                    | 18                      | 126         | 110              | 15                       | 17                         | 56.3 (8.1)              | 28.2 (4.5)            | 97.9 (11.8)              | 174.9 (6.8)  |
| 2 (7.95–10.64)                  | 555               | 352          | 203           | 86                        | 15                                | 40                    | 22                      | 111         | 118              | 35                       | 14                         | 56.7 (8.1)              | 27.8 (4.1)            | 96.8 (11.1)              | 175.8 (6.8)  |
| 3 (10.65–144.52)                | 562               | 336          | 226           | 81                        | 13                                | 32                    | 16                      | 111         | 77               | 60                       | 23                         | 56.6 (8.3)              | 27.5 (4.0)            | 95.9 (10.9)              | 176.2 (6.9)  |
| 1 (1.08–6.36)                   | 462               | 342          | 226           | 21                        | 24                                | 16                    | 16                      | 110         | 76               | 60                       | 23                         | 56.1 (7.9)              | 27.9 (5.4)            | 86.7 (12.9)              | 161.8 (6.3)  |
| 2 (6.37–8.41)                   | 428               | 302          | 120           | 16                        | 21                                | 11                    | 16                      | 110         | 98               | 60                       | 18                         | 56.6 (7.9)              | 27.0 (5.1)            | 84.4 (12.3)              | 162.5 (6.3)  |
| 3 (8.42–115.75)                 | 381               | 287          | 94            | 10                        | 20                                | 5                     | 9                       | 80          | 80               | 57                       | 25                         | 55.7 (8.2)              | 26.3 (4.9)            | 82.7 (12.0)              | 163.1 (6.3)  |
Table 1. Cont.

| Baseline Characteristic                      | Log-Total Bilirubin Tertile (µM/L) |
|--------------------------------------------|------------------------------------|
|                                            | Men                                | Women                             |
|                                            | 1 (1.43–7.94)                      | 2 (7.95–10.64)                    |
|                                            | 3 (10.65–144.52)                   | 1 (1.08–6.36)                     |
|                                            | 2 (6.37–8.41)                      | 3 (8.42–115.75)                   |
| Cases (N)                                  |                                    |                                   |
| Smoking status (%)                         |                                    |                                   |
| Never                                      | 30                                 | 34                                 |
| Former                                     | 33                                 | 34                                 |
| Current                                    | 49                                 | 29                                 |
|                                            |                                    | 21                                 |
|                                            |                                    | 46                                 |
|                                            |                                    | 31                                 |
|                                            |                                    | 23                                 |
| Alcohol consumption status (%)             |                                    |                                   |
| Never                                      | 39                                 | 30                                 |
| Former                                     | 41                                 | 30                                 |
| Current                                    | 33                                 | 34                                 |
|                                            |                                    | 34                                 |
|                                            |                                    | 34                                 |
|                                            |                                    | 34                                 |
| Physical activity (MET§ hour/week) (%)     |                                    |                                   |
| <10                                        | 36                                 | 33                                 |
|                                            | 31                                 | 36                                 |
|                                            |                                    | 33                                 |
|                                            |                                    | 31                                 |
|                                            |                                    | 34                                 |
|                                            |                                    | 35                                 |
|                                            |                                    |                                   |
| >60                                        | 34                                 | 33                                 |
|                                            |                                    | 33                                 |
|                                            |                                    | 31                                 |
|                                            |                                    | 34                                 |
|                                            |                                    | 35                                 |
| Education (%)                              |                                    |                                   |
| College/university degree                  | 31                                 | 33                                 |
|                                            | 36                                 | 30                                 |
|                                            |                                    | 33                                 |
|                                            |                                    | 36                                 |
|                                            |                                    | 36                                 |
| Family history of CRC (%)                  |                                    |                                   |
| Yes                                        | 33                                 | 34                                 |
|                                            | 34                                 | 33                                 |
|                                            |                                    | 34                                 |
|                                            |                                    | 33                                 |
|                                            |                                    | 34                                 |
|                                            |                                    | 33                                 |
| Prevalent diabetes (%)                     |                                    |                                   |
| Yes                                        | 41                                 | 30                                 |
|                                            | 29                                 | 42                                 |
|                                            |                                    | 30                                 |
|                                            |                                    | 28                                 |
| Aspirin/Ibuprofen Use (%)                  |                                    |                                   |
| Yes                                        | 34                                 | 33                                 |
|                                            | 33                                 | 35                                 |
|                                            |                                    | 33                                 |
|                                            |                                    | 32                                 |
| Red and processed meat (%)                 |                                    |                                   |
| <2/week                                    | 31                                 | 34                                 |
|                                            | 35                                 | 32                                 |
|                                            |                                    | 32                                 |
|                                            |                                    | 33                                 |
| ≥4/week                                    | 35                                 | 33                                 |
|                                            | 32                                 | 33                                 |
|                                            |                                    | 32                                 |
| Ever use of hormone therapy (%) ¤          |                                    |                                   |
| Yes                                        |                                    | 35                                 |
|                                            |                                    | 34                                 |
|                                            |                                    | 31                                 |

Mean and standard deviation. § MET = metabolic equivalents. ¤ Only among women.

The distribution of bilirubin levels was positively skewed with geometric means of 9.51 µM/L (95% CI 9.49–9.52) for men and 7.56 µM/L (95% CI 7.55–7.58) for women, which were within the clinical reference range of bilirubin levels (5–17 µM/L).

The reproducibility (ICC) of total bilirubin levels measured at both the recruitment and repeat assessment visit (n = 15,611 participants; median of 4 years apart) was 0.72 (95% CI 0.71–0.73) for both sexes.

3.2. Associations between Total Bilirubin Levels and Risk of GI Cancers

In the multivariable model, circulating total bilirubin levels were negatively associated with risk of CRC (HR per 1-SD increment in log-total bilirubin levels 0.95, 95% CI 0.88–1.02, p = 0.14) (Table ??), with similar associations found for men and women (P-heterogeneity = 0.48). Evidence of non-linearity (U-shaped) of the association between total bilirubin levels and CRC was found (p = 0.02) (Figure ??A). The dose–response anal-
ysis using restricted cubic splines indicated a threshold level of circulating bilirubin of approximately 10 µM/L, after which the negative association plateaued (Figure ??A).

**Table 2.** Risk (hazard ratios) of gastrointestinal cancers associated with circulating total bilirubin levels in the UK Biobank.

| Cancer Type                     | Both Sexes |  |  |
|---------------------------------|------------|----------------|----------------|
|                                 | Men        | Women         |  |
| Colorectal Cancer (CRC)         |  |  |  |
| N cases                         | 3002       | 1731           | 1271           |
| Crude HR (95% CI) *             | 0.93 (0.87–1.00) | 0.92 (0.85–1.01) | 0.96 (0.86–1.06) |
| p                               | 0.05       | 0.07           | 0.39           |
| HR (95% CI) **                  | 0.95 (0.88–1.02) | 0.93 (0.85–1.02) | 0.98 (0.88–1.09) |
| p                               | 0.14       | 0.11           | 0.74           |
| P non-linearity                 | 0.02       | N/A            | N/A            |
| Colon Cancer                    |  |  |  |
| N cases                         | 1989       | 1058           | 931            |
| Crude HR (95% CI) *             | 0.93 (0.85–1.01) | 0.91 (0.81–1.01) | 0.96 (0.85–1.08) |
| p                               | 0.08       | 0.08           | 0.49           |
| HR (95% CI) **                  | 0.95 (0.87–1.04) | 0.92 (0.82–1.03) | 1.00 (0.88–1.13) |
| p                               | 0.26       | 0.15           | >0.9           |
| P non-linearity                 | 0.07       | N/A            | N/A            |
| Rectal Cancer                   |  |  |  |
| N cases                         | 1013       | 673            | 340            |
| Crude HR (95% CI) *             | 0.95 (0.84–1.07) | 0.95 (0.82–1.09) | 0.95 (0.78–1.16) |
| p                               | 0.38       | 0.48           | 0.61           |
| HR (95% CI) **                  | 0.94 (0.83–1.07) | 0.93 (0.80–1.09) | 0.97 (0.77–1.21) |
| p                               | 0.36       | 0.37           | 0.76           |
| P non-linearity                 | 0.29       | N/A            | N/A            |
| Esophageal Adenocarcinoma (EAC) |  |  |  |
| N cases                         | 338        | 291            | 47             |
| Crude HR (95% CI) *             | 0.69 (0.55–0.87) | 0.72 (0.56–0.91) | 0.60 (0.33–1.10) |
| p                               | 0.002      | 0.01           | 0.10           |
| HR (95% CI) **                  | 0.72 (0.56–0.92) | 0.74 (0.56–0.97) | 0.84 (0.40–1.78) |
| p                               | 0.01       | 0.03           | 0.65           |
| P non-linearity                 | 0.06       | N/A            | N/A            |
| Esophageal Squamous-Cell Carcinoma (ESCC) |  |  |  |
| N cases                         | 124        | 59             | 65             |
| Crude HR (95% CI) *             | 0.82 (0.55–1.21) | 0.77 (0.40–1.48) | 0.86 (0.55–1.35) |
| p                               | 0.32       | 0.43           | 0.51           |
| HR (95% CI) **                  | 0.74 (0.44–1.24) | N/A            | 0.68 (0.33–1.39) |
| p                               | 0.25       | N/A            | 0.29           |
| P non-linearity                 | N/A        | N/A            | 0.11           |
| Stomach Cardia Cancer           |  |  |  |
| N cases                         | 139        | 113            | 26             |
| Crude HR (95% CI) *             | 1.01 (0.71–1.45) | 1.14 (0.77–1.67) | 0.53 (0.20–1.43) |
Table 2. Cont.

|                          | Both Sexes | Men        | Women      |
|--------------------------|------------|------------|------------|
|                          |            |            |            |
|                          | *          |            |            |
| p                        | 0.07       | 0.51       | 0.21       |
| HR (95% CI) **           | 1.33 (0.84–2.11) | 1.59 (0.90–2.82) | N/A       |
| p                        | 0.23       | 0.11       | N/A        |
| Pnon-linearity           | 0.86       | N/A        | N/A        |

|                          |            |            |            |
|                          |            |            |            |
| Stomach Non-Cardia Cancer|            |            |            |
| N cases                  | 92         | 56         | 36         |
| Crude HR (95% CI) *      | 0.67 (0.36–1.26) | 0.83 (0.37–1.87) | 0.56 (0.24–1.33) |
| p                        | 0.22       | 0.66       | 0.19       |
| HR (95% CI) **           | 0.88 (0.41–1.91) | 3.23 (0.44–23.61) | 0.15 (0.00–7.60) |
| p                        | 0.74       | 0.25       | 0.34       |
| Pnon-linearity           | N/A        | N/A        | N/A        |

|                          |            |            |            |
|                          |            |            |            |
| Oral Cancer              |            |            |            |
| N cases                  | 524        | 347        | 177        |
| Crude HR (95% CI) *      | 0.89 (0.75–1.05) | 0.85 (0.69–1.06) | 0.96 (0.74–1.24) |
| p                        | 0.17       | 0.14       | 0.75       |
| HR (95% CI) **           | 0.93 (0.77–1.13) | 0.94 (0.73–1.20) | 1.01 (0.75–1.35) |
| p                        | 0.46       | 0.61       | >0.9       |
| Pnon-linearity           | >0.9       | N/A        | N/A        |

|                          |            |            |            |
|                          |            |            |            |
| Pancreatic Cancer        |            |            |            |
| N cases                  | 559        | 305        | 254        |
| Crude HR (95% CI) *      | 0.94 (0.81–1.09) | 0.87 (0.70–1.06) | 1.03 (0.84–1.25) |
| p                        | 0.40       | 0.16       | 0.78       |
| HR (95% CI) **           | 0.96 (0.82–1.13) | 0.83 (0.65–1.04) | 1.11 (0.89–1.38) |
| p                        | 0.62       | 0.11       | 0.36       |
| Pnon-linearity           | N/A        | N/A        | N/A        |

|                          |            |            |            |
|                          |            |            |            |
| Hepatocellular Carcinoma (HCC) |        |            |            |
| N cases                  | 135        | 110        | 25         |
| Crude HR (95% CI) *      | 1.65 (1.21–2.49) | 1.57 (1.08–2.29) | 1.69 (1.03–2.79) |
| p                        | 0.002      | 0.02       | 0.04       |
| HR (95% CI) **           | 2.07 (1.15–3.73) | 1.54 (0.62–3.27) | N/A        |
| p                        | 0.02       | 0.26       | N/A        |
| Pnon-linearity           | 0.02       | N/A        | N/A        |

|                          |            |            |            |
|                          |            |            |            |
| Intrahepatic Bile Duct (IBD) Cancer |        |            |            |
| N cases                  | 120        | 54         | 66         |
| Crude HR (95% CI) *      | 1.37 (0.69–1.96) | 1.42 (0.86–2.36) | 1.29 (0.81–2.06) |
| p                        | 0.08       | 0.17       | 0.29       |
| HR (95% CI) **           | 1.67 (1.07–2.62) | 5.59 (0.88–35.75) | 1.40 (0.78–2.50) |
Cancers was modeled by restricted cubic splines with 3 knots at percentiles 10th, 50th, and 90th in a regression model to evaluate the proportional hazard regression (solid line) with 95% confidence intervals (dashed lines) for the association between total bilirubin levels (µM/L) and the incident colorectal cancer.

Figure 1. Cubic spline modeling of bilirubin levels in relation to cancer risk. This graph shows multivariable-adjusted cox proportional hazard regression (solid line) with 95% confidence intervals (dashed lines) for the association between total bilirubin levels (µM/L) and the incident colorectal cancer (A), and esophageal adenocarcinoma (B) from the UK Biobank. It was modeled by restricted cubic splines with 3 knots at percentiles 10th, 50th, and 90th in a regression model to evaluate the linearity hypothesis.

Circulating total bilirubin levels were negatively associated with EAC risk (HR per 1-SD increment in log-total bilirubin levels 0.72, 95%CI 0.56–0.92, p = 0.01) (Table ??), with similar associations found for men and women (P-heterogeneity = 0.55). Evidence of non-linearity (U-shaped) of the association between total bilirubin levels and EAC was found (p = 0.06) (Figure ??B). The dose–response analysis using restricted cubic splines showed a shape of association similar to CRC with an observed lowest risk between 10 and 13 µM/L of total bilirubin (Figure ??B). Total bilirubin levels were also negatively related to ESCC risk, although this association did not reach the threshold of statistical significance (Table ??). We found little evidence that total bilirubin levels were associated with risks of stomach cardia, stomach non-cardia, and oral cancers. There was suggestive evidence that associations between total bilirubin levels and risk of pancreatic cancer differed by sex (P-heterogeneity = 0.05), with HRs equal to 0.83 (95%CI 0.65–1.04) and 1.11 (0.89–1.38) for men and women, respectively, although these associations did not reach the threshold of statistical significance. Total bilirubin levels were positively associated with risks of HCC (HR per 1-SD increment in circulating log-total bilirubin levels, 2.07, 95%CI 1.15–3.73) and IBD cancer (HR per 1-SD increment in circulating log-total bilirubin levels, 1.67, 95%CI 1.07–2.62) in the continuous models. There was evidence of non-linearity for HCC, which,

### Table 2. Cont.

| Cancer Types | Both Sexes | Men | Women |
|--------------|------------|-----|-------|
| p            | 0.03       | 0.07| 0.25  |
| Pnon-linearity | >0.9       | N/A | N/A   |

HR: hazard ratio, CI: confidence interval, N/A: not available or not assessed. All HRs are per 1-SD increment in circulating log-total bilirubin levels. * The crude multivariable cox regression model stratified by sex, Townsend deprivation index (quintiles), region of the recruitment assessment center, and age at recruitment. ** The multivariable models were adjusted for waist circumference (per 5 cm), smoking status and intensity (never, former, current-< 15/day, current- > 15/day, current- intensity unknown, unknown), alcohol consumption frequency (never, special occasions only, 1–3 times/month, 1–2 times/week, 3–4 times/week, daily/almost daily, unknown), and qualification (Certificates of secondary education/Ordinary-levels/General Certificates of Secondary Education or equivalent, National Vocational Qualification/Higher National Diploma/Higher National Certificate/Advanced-levels/Advanced Subsidiary-levels or equivalent, other professional qualifications, college/university degree, none of the above). The HCC and IBD cancer models were further adjusted for total physical activity (<10, 10–19.9, 20–39.9, 40–59.9, ≥60 metabolic equivalent hours/week), and height (per 10 cm). The pancreatic cancer model was further adjusted for prevalent diabetes [? ] and the CRC model was additionally adjusted for frequency of red and processed meat consumption (<2, 2–2.99, 3–3.99, ≥4 occasions/week), family history of CRC (no/yes), total intake of fruit and vegetable (tablespoons/day), regular aspirin/ibuprofen use (no/yes), and ever use of menopausal hormone therapy (no/yes).
however, was likely due to the limited number of events in the lower or higher distributions of total bilirubin.

3.3. Subgroup and Sensitivity Analyses

There was little evidence of heterogeneity for the associations between total bilirubin levels and risk of GI cancers according to subgroups of other risk factors with a few exceptions. For ESCC (P-heterogeneity = 0.01) and pancreatic cancer (P-heterogeneity = 0.008), we detected heterogeneity according to smoking status, with negative associations, albeit not statistically significant, only found for never smokers (Table S1).

We also found evidence of heterogeneity of the total bilirubin and IBD cancer risk according to BMI (P-heterogeneity = 0.0004), with a positive association only found for the above median BMI group. Results were generally similar when GI cancer cases occurring during the first two years of follow-up were excluded, except for CRC, where the association was attenuated and became null (HR per 1-SD increment in circulating log-total bilirubin levels, 1.03, 95%CI 0.95–1.13) (Table ??).

The results were similar after adjusting the HR (and 95%CI) for regression dilution using the RDR (Table S2) and for direct and indirect bilirubin (Tables S3 and S4). Excluding participants ($n = 560$) in the highest decile of circulating levels of ALT, AST, ALP, and GGT, did not alter our results (Table S5).

| Cancer Types                                      | HR (95%CI)          | p       |
|--------------------------------------------------|---------------------|---------|
| Colorectal cancer (CRC)                          |                     |         |
| Both sexes                                       | 1.03 (0.95–1.13)    | 0.46    |
| Men                                              | 0.98 (0.88–1.10)    | 0.73    |
| Women                                            | 1.13 (0.99–1.29)    | 0.07    |
| Colon cancer                                     |                     |         |
| Both sexes                                       | 1.07 (0.96–1.20)    | 0.20    |
| Men                                              | 0.98 (0.85–1.14)    | 0.80    |
| Women                                            | 1.21 (1.03–1.42)    | 0.02    |
| Rectal cancer                                    |                     |         |
| Both sexes                                       | 1.00 (0.85–1.17)    | >0.90   |
| Men                                              | 1.02 (0.84–1.24)    | 0.83    |
| Women                                            | 1.05 (0.79–1.40)    | 0.73    |
| Esophageal adenocarcinoma (EAC)                  |                     |         |
| Both sexes                                       | 0.76 (0.56–1.03)    | 0.07    |
| Men                                              | 0.76 (0.53–1.08)    | 0.13    |
| Women                                            | 1.58 (0.55–4.53)    | 0.40    |
| Esophageal squamous-cell carcinoma (ESCC)        |                     |         |
| Both sexes                                       | 0.50 (0.22–1.13)    | 0.10    |
| Stomach cardia cancer                            |                     |         |
| Both sexes                                       | 1.45 (0.77–2.73)    | 0.25    |
| Stomach non-cardia cancer                        |                     |         |
| Both sexes                                       | 0.45 (0.15–1.36)    | 0.16    |
| Oral cancer                                      |                     |         |
| Both sexes                                       | 0.95 (0.75–1.21)    | 0.68    |
Table 3. Cont.

| Cancer Types                     | HR (95%CI)       | p    |
|----------------------------------|------------------|------|
| Men                              | 0.92 (0.67–1.26) | 0.61 |
| Women                            | 0.97 (0.65–1.47) | 0.90 |
| Pancreatic cancer                 |                  |      |
| Both sexes                       | 0.97 (0.80–1.16) | 0.72 |
| Men                              | 0.77 (0.58–1.02) | 0.07 |
| Women                            | 1.19 (0.92–1.54) | 0.19 |
| Hepatocellular carcinoma (HCC)    |                  |      |
| Both sexes                       | 2.01 (1.10–3.68) | 0.02 |
| Intrahepatic bile duct (IBD) cancer |       |      |
| Both sexes                       | 1.36 (0.81–2.30) | 0.30 |

HR: hazard ratio, CI: confidence interval. Multivariable-adjusted Cox proportional hazard regression models (HR per 1-SD increment in circulating log-total bilirubin levels), N = 431,500.

4. Discussion

In this large-scale prospective study, higher pre-diagnostic circulating levels of total bilirubin were strongly negatively associated with risk of EAC. This finding was consistent for men and women and after stratification by BMI and smoking status. We found positive associations between circulating total bilirubin levels and risks of HCC and IBD cancer. For CRC, the negative association found in our main analysis was likely a consequence of reverse causality. Nevertheless, circulating bilirubin could be useful for detecting the presence of subclinical disease.

Oxidative-stress-induced damage to DNA is accepted as a major contributing factor to carcinogenesis [? ]. As bilirubin is a potent antioxidant, it may protect against malignancy [? ]; however, the exact mechanisms of the anticarcinogenic effects of bilirubin are still not completely understood. Experimental data [? ? ] support a role for bilirubin and its downstream signaling pathways in tumorigenesis. Ollinger et al. have found that bilirubin can induce cell cycle arrest and apoptosis in abnormally proliferating cells and contributes to the defense against cancer by interfering with procarcinogenic signaling pathways [? ].

We are not aware of other prospective epidemiological studies investigating the role of circulating levels of bilirubin in esophageal cancer development. Dura et al. [? ] found in a case-control study with esophageal cancer patients (n cases = 351 Caucasians) that genetically predicted high activity of UGT1A1, which is predictive of low serum levels of bilirubin, was associated with an increased risk of ESCC. However, since ESCC is rare in the Netherlands, they could not firmly establish their findings. A direct protective effect of the UGT1A1 enzyme may not be present in the esophagus, as this enzyme is not highly expressed in esophageal cells, whereas a systemic effect of circulating bilirubin could be exerted [? ? ]. The results of our study are compatible with this hypothesis and support further studies on the utility of circulating bilirubin as a routinely collected biomarker for EAC risk-stratification.

The positive associations found in our analyses for total bilirubin and HCC and IBD cancer risk were consistent with a prior nested case-control study in the European Prospective Investigation into Cancer and nutrition (EPIC) cohort [? ]. Abnormally high bilirubin levels in patients with HCC were also associated (≥25.7 µM/L) with cancer aggressiveness [? ]. As bilirubin is conjugated by UGT1A1 in the liver, liver dysfunction may result in higher circulating bilirubin levels due to some underlying liver disease process [? ] and correlates with the severity of the illness [? ? ].

For CRC, the negative association in our main analysis was attenuated when participants with less than 2 years of follow-up were excluded, which is suggestive of reverse causation, whereby subclinical diseases also affect circulating bilirubin levels. In our re-
cent case-control study, nested in the prospective EPIC cohort [? ], we found that higher circulating levels of unconjugated bilirubin, the main component of total bilirubin, were positively associated with CRC risk in men and negatively associated in women [? ]. Possible explanations for the inconsistent results found between EPIC and the current study are unclear. Some of this heterogeneity may be explained by differences in study designs, limited sample size in previous studies, and measurements of total bilirubin levels or its components [? ? ? ? ? ]. However, there may also be heterogeneity related to population sub-group characteristics, especially by sex and UGT1A1 genotype, which suggests that further refined analyses are needed.

We found little evidence that total bilirubin was associated with oral cancer risk. Lacko et al. [? ] found no association between the UGT1A1*28 polymorphism and risk of the oral cavity. Cancer causing types of human papilloma virus (HPV) is the leading cause of oropharyngeal cancers. To our knowledge, there is no evidence that the antioxidative/anticarcinogenic role of bilirubin can affect the carcinogenic action of HPV. The expression of UGT1A1 is low in the oropharynx, which precludes a direct protective role of this enzyme; however, an indirect effect of circulating bilirubin cannot be excluded [? ].

To our knowledge, this is the first prospective study investigating the association between circulating bilirubin levels with risks of stomach and pancreatic cancer and, overall, we found little evidence of associations. However, the suggestive evidence (p-heterogeneity = 0.05 did not reach our set level of significance = 0.002) for differences among men and women deserves further investigation. Sex hormones, which are known to influence UGT1A1 activity [? ], and differences in UGT1A1 expression between men and women, leading to differential circulating levels [? ], might partly explain the sex differences in pancreatic cancer risk. We previously reported suggestive evidence of differences between men and women related to risk of pancreatic cancer [? ] and CRC [? ] using a genetic instrument approach, yet opposite in direction (suggestive higher risk in men and lower risk in women) compared to the present analysis. Our sex-stratified findings for pancreatic cancer could therefore also be due to chance.

This was the most comprehensive study to examine the associations between circulating bilirubin levels and GI cancer risk. This allowed us to directly compare associations across different cancer types with uniform confounder adjustments, and to suggest a range of total bilirubin levels associated with the lowest risk of developing certain types of cancer (i.e., 10–13 µM/L, EAC and CRC). These are novel and potentially important thresholds regarding cancer risk, but replication with a larger number of events is needed. Uniquely, our study followed a full cohort, rather than a nested case-control study design, as bilirubin levels were measured in all UKB participants. The availability of repeat total bilirubin measurements in a subset of participants (n = 15,611) meant we were able to correct our HRs for regression dilution bias, thereby diminishing the effects of measurement error and within-person variability. A limitation of our study was that for most participants total bilirubin levels were measured once at baseline. However, our reproducibility analysis using the repeated bilirubin measures from a subset of participants collected over a median of 4 years apart found an ICC value of 0.72, demonstrating that a single measure of bilirubin levels provides a fairly good estimate of longer-term exposure. A further limitation was the low number of events for some cancer sites, which resulted in relatively wide confidence intervals, particularly for hepatocellular carcinoma (N cases = 135), intrahepatic bile duct (N cases = 120), and to some extent also EAC (N cases = 338).

5. Conclusions

In this comprehensive analysis of circulating total bilirubin levels and GI cancer risk, we found a novel and robust negative association for EAC risk. If this association is validated in subsequent studies, circulating bilirubin measurements could be used to risk stratify people at higher risk of developing EAC. We further observed a weak and less robust negative association between total bilirubin levels and CRC risk and positive associations with risks of HCC and IBD.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/cancers13112749/s1, Table S1. The association between circulation total bilirubin levels and gastrointestinal cancers risk across strata of potential effect modifiers in the UK Biobank, Table S2. Risk (hazard ratios) of gastrointestinal cancers associated with circulating bilirubin levels corrected for regression dilution in the UK Biobank, Table S3. Risk (hazard ratios) of gastrointestinal cancers associated with direct bilirubin levels in the UK Biobank, Table S4. Risk (hazard ratios) of gastrointestinal cancers associated with indirect bilirubin levels in the UK Biobank, Table S5. Risk (hazard ratios) of gastrointestinal cancers associated with circulating bilirubin levels adjusted by liver enzymes in the UK Biobank.

Author Contributions: Conceptualization, N.M. and H.F.; methodology, N.M. and H.F.; software, N.S.K.; validation, N.M. and H.F.; formal analysis, N.S.K.; investigation, All authors; resources, N.M.; writing—original draft preparation, N.S.K.; writing—review and editing, All coauthors had the opportunity to comment on the analysis and interpretation of the findings and approved the final version for publication; supervision, H.F., N.M. and K.-H.W.; project administration, H.F. and K.-H.W.; funding acquisition, H.F. and K.-H.W., N.S.K., K.-H.W., R.C.-T., M.J.G., N.M. and H.F. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Austrian Science Fund (FWF, grant nr. P 29608) and the French National Cancer Institute (INCa, grant nr. 2016-043).

Institutional Review Board Statement: The UKB obtained full ethical approval from the North West Multi-centre Research Ethics Committee, the National Information Governance Board for Health and Social Care in England and Wales, and the Community Health Index Advisory Group in Scotland. Additionally, in 2004, an independent Ethics and Governance Council was formed to oversee UKB’s continuous adherence to the Ethics and Governance Framework that was developed for the study (http://www.ukbiobank.ac.uk/ethics/, accessed on 3 July 2019). All participants provided written informed consent.

Data Availability Statement: The UK Biobank resource is available to bona fide researchers for health-related research in the public interest. All researchers who wish to access the research resource must register with UK Biobank by completing the registration form in the Access Management System (AMS—https://bbams.ndph.ox.ac.uk/ams/, accessed on 3 July 2019). Analytic codes will be made available to other researchers upon request.

Acknowledgments: UKB is an open access resource. Bona fide researchers can apply to use the UKB dataset by registering and applying at http://ukbiobank.ac.uk/register-apply/ (accessed on 3 July 2019). This work was conducted using the UKB Resource under Application Number 25897 and we express our gratitude to the participants and those involved in building the resource.

Conflicts of Interest: The authors declare no conflict of interest. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer/World Health Organization.

References
1. Arnold, M.; Abnet, C.C.; Neale, R.E.; Vignat, J.; Giovannucci, E.L.; McGlynn, K.A.; Bray, F. Global Burden of 5 Major Types of Gastrointestinal Cancer. *Gastroenterology* 2020, 159, 335–349.e15. [CrossRef] [PubMed]
2. Atay, A.E.; Esen, B.; Gokmen, E.S. Chapter 3—Oxidative Stress and Gastrointestinal System Cancers. In *Gastrointestinal Tissue, Oxidative Stress and Dietary Antioxidants*; Academic Press: Cambridge, MA, USA, 2017; pp. 29–51.
3. García-Guede, Á.; Vera, O.; Ibáñez-de-Caceres, I. When Oxidative Stress Meets Epigenetics: Implications in Cancer Development. *Antioxidants* 2020, 9, 468. [CrossRef] [PubMed]
4. Bjelakovic, G.; Nikolova, D.; Simonetti, R.G.; Gluud, C. Antioxidant supplements for preventing gastrointestinal cancers. *Cochrane Database Syst. Rev.* 2008, Cd004183. [CrossRef]
5. Kurutas, E.B. The importance of antioxidants which play the role in cellular response against oxidative/nitrosative stress: Current state. *Nutr. J.* 2016, 15, 71. [CrossRef]
6. Favery, J. Bilirubin in clinical practice. A review. *Liver Int.* 2008, 28, 592–605. [CrossRef]
7. Hansen, T.W.; Mathiesen, S.B.; Walaas, S.I. Bilirubin has widespread inhibitory effects on protein phosphorylation. *Pediatric Res.* 1996, 39, 1072–1077. [CrossRef]
8. Rodrigues, C.M.; Sola, S.; Brito, M.A.; Brites, D.; Moura, J.J. Bilirubin directly disrupts membrane lipid polarity and fluidity, protein order, and redox status in rat mitochondria. *J. Hepatol.* 2002, 36, 335–341. [CrossRef]
9. Sedlak, T.W.; Saleh, M.; Higginson, D.S.; Paul, B.D.; Juluri, K.R.; Snyder, S.H. Bilirubin and glutathione have complementary antioxidant and cytoprotective roles. *Proc. Natl. Acad. Sci. USA* 2009, 106, 5171–5176. [CrossRef]
10. Wagner, K.H.; Wallner, M.; Mölzer, C.; Gazzin, S.; Bulmer, A.C.; Tiribelli, C.; Vitek, L. Looking to the horizon: The role of bilirubin in the development and prevention of age-related chronic diseases. *Clin. Sci.* 2015, 129, 1–25. [CrossRef]
11. DiNicolantonio, J.J.; McCarty, M.F.; O’Keefe, J.H. Antioxidant bilirubin works in multiple ways to reduce risk for obesity and its health complications. *Open Heart* 2018, 5, e000914. [CrossRef]
12. Freisling, H.; Seyed Khoei, N.; Viallon, V.; Wagner, K.H. Gilbert’s syndrome, circulating bilirubin and lung cancer: A genetic advantage? *Thorax* 2020, 75, 916–917. [CrossRef]
13. Seyed Khoei, N.; Jenab, M.; Murphy, N.; Banbury, B.L.; Carreras-Torres, R.; Viallon, V.; Kühn, T.; Bueno-de-Mesquita, B.; Aleksandrova, K.; Cross, A.J.; et al. Circulating bilirubin levels and risk of colorectal cancer: Serological and Mendelian randomization analyses. *BMC Med.* 2020, 18, 229. [CrossRef]
14. Beutler, E.; Gelbart, T.; Demina, A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism? *Proc. Natl. Acad. Sci. USA* 1998, 95, 8170–8174. [CrossRef]
15. Horsfall, L.J.; Burgess, S.; Hall, I.; Nazareth, I. Genetically raised serum bilirubin levels and lung cancer: A cohort study and Mendelian randomisation using UK Biobank. *Thorax* 2020, 75, 955–964. [CrossRef]
16. Horsfall, L.J.; Zeitlyn, D.; Tarek, A.; Bekele, E.; Thomas, M.G.; Bradman, N.; Swallow, D.M. Prevalence of clinically relevant UGT1A alleles and haplotypes in African populations. *Ann. Hum. Genet.* 2011, 75, 236–246. [CrossRef]
17. The Human Protein Atlas. Available online: https://www.proteinatlas.org/ENSG00000241635-UGT1A1/tissue (accessed on 1 February 2021).
18. Hamoud, A.-R.; Weaver, L.; Stec, D.E.; Hinds, T.D., Jr. Bilirubin in the Liver-Gut Signaling Axis. *Trends Endocrinol. Metab.* TEM 2018, 29, 140–150. [CrossRef]
19. Mölzer, C.; Huber, H.; Diem, K.; Wallner, M.; Bulmer, A.C.; Wagner, K.H. Extracellular and intracellular anti-mutagenic effects of bile pigments in the Salmonella typhimurium reverse mutation assay. *Toxicol. In Vitro* 2013, 27, 433–437. [CrossRef]
20. Mölzer, C.; Huber, H.; Steyrer, A.; Ziesel, G.; Ertl, A.; Plavotic, A.; Wallner, M.; Bulmer, A.C.; Wagner, K.H. In vitro antioxidant capacity and antigentoxic properties of protoporphyrin and structurally related tetrapyroles. *Free Radic. Res.* 2012, 46, 1369–1377. [CrossRef]
21. Mölzer, C.; Huber, H.; Steyrer, A.; Ziesel, G.V.; Wallner, M.; Hong, H.T.; Blanckfield, J.T.; Bulmer, A.C.; Wagner, K.-H. Bilirubin and related tetrapyroles inhibit food-borne mutagenesis: A mechanism for antigenotoxic action against a model epoxide. *J. Nat. Prod.* 2013, 76, 1958–1965. [CrossRef]
22. Mölzer, C.; Pfleger, B.; Putz, E.; Roßmann, A.; Schwarz, U.; Wallner, M.; Bulmer, A.C.; Wagner, K.H. In vitro DNA-damaging effects of intestinal and related tetrapyroles in human cancer cells. *Exp. Cell Res.* 2013, 319, 536–545. [CrossRef]
23. Seyed Khoei, N.; Anton, G.; Peters, A.; Freisling, H.; Wagner, K.H. The Association between Serum Bilirubin Levels and Colorectal Cancer Risk: Results from the Prospective Cooperative Health Research in the Region of Augsburg (KORA) Study in Germany. *Antioxidants* 2020, 9, 908. [CrossRef]
24. Stepien, M.; Fedirko, V.; Duarte-Salles, T.; Ferrari, P.; Freisling, H.; Trepo, E.; Trichopoulou, A.; Bamia, C.; Weiderpass, E.; Olsen, A.; et al. Prospective association of liver function biomarkers with development of hepatobiliary cancers. *Cancer Epidemiol.* 2016, 40, 179–187. [CrossRef]
25. Dura, P.; Salomon, J.; Te Morsche, R.H.; Roelofs, H.M.; Kristinsson, J.O.; Wobbes, T.; Witteman, B.J.; Tan, A.C.; Drenth, J.P.; Peters, W.H. High enzyme activity UGT1A1 or low activity UGT1A8 and UGT2B4 genotypes increase esophageal cancer risk. *Int. J. Oncol.* 2012, 40, 1789–1796.
26. Lacko, M.; Roelofs, H.M.; Morsche, R.H.T.; Voogd, A.C.; Opheus, M.B.O.; Peters, W.H.; Manji, J.J. Genetic polymorphism in the conjugating enzyme UGT1A1 and the risk of head and neck cancer. *Int. J. Cancer* 2010, 127, 2815–2821. [CrossRef]
27. Jirásková, A.; Novotný, J.; Novotný, L.; Vodička, P.; Pardini, B.; Naccarati, A.; Schwertner, H.A.; Hubáček, J.A.; Punčochářová, L.; Šmerhovský, Z.; et al. Association of serum bilirubin and promoter variations in HMOX1 and UGT1A1 genes with sporadic colorectal cancer. *Int. J. Cancer* 2012, 131, 1549–1555. [CrossRef]
28. Bajro, M.H.; Josifovski, T.; Panovski, M.; Jankulovski, N.; Nestorovska, A.K.; Matevska, N.; Petrulevska, N.; Dimovski, A.J. Promoter length polymorphism in UGT1A1 and the risk of sporadic colorectal cancer. *Cancer Genet.* 2012, 205, 163–167. [CrossRef]
29. Sudlow, C.; Gallagher, J.; Allen, N.; Beral, V.; Burton, P.; Danesh, J.; Downey, P.; Elliott, P.; Green, J.; Landray, M.; et al. UK biobank: An open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med.* 2015, 12, e1001779. [CrossRef]
30. Fry, D.; Almond, R.; Moffat, S.; Gordon, M.; Singh, P. UK Biobank Biomarker Project—Companion Document to Accompany Serum Biomarker Data; Prepared for UK Biobank Showcase; UK Biobank: Stockport, UK, 2019.
31. WHO. Available online: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577 (accessed on 1 July 2019).
32. World Cancer Research Fund. 2018. Available online: https://www.wcrf.org/dietandcancer/resources-and-toolkit (accessed on 1 July 2019).
33. Murphy, N.; Knuppel, A.; Papadimitriou, N.; Martin, R.M.; Tsilidis, K.K.; Smith-Byrne, K.; Fensom, G.; Perez-Cornago, A.; Travis, R.C.; Key, T.J.; et al. Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: Observational and Mendelian randomization analyses with ~430,000 women. *Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.* 2020, 31, 641-649. [CrossRef]

34. Waris, G.; Ahsan, H. Reactive oxygen species: Role in the development of cancer and various chronic conditions. *J. Carcinog.* 2006, 5, 14. [CrossRef]

35. Grant, D.J.; Bell, D.A. Bilirubin UDP-glucuronosyltransferase 1A1 gene polymorphisms: Susceptibility to oxidative damage and cancer? *Mot. Carcinog.* 2000, 29, 198–204. [CrossRef]

36. Keshavan, P.; Schwemberger, S.J.; Smith, D.L.; Babcock, G.F.; Zucker, S.D. Unconjugated bilirubin induces apoptosis in colon cancer cells by triggering mitochondrial depolarization. *Int. J. Cancer* 2004, 112, 433–445. [CrossRef]

37. Ollinger, R.; Kogler, P.; Troppmair, J.; Herrmann, M.; Wurm, M.; Drasche, A.; Konigsrainer, I.; Amberger, A.; Weiss, H.; Ofner, D.; et al. Bilirubin inhibits tumor cell growth via activation of ERK. *Cell Cycle* 2007, 6, 3078–3085. [CrossRef]

38. Rao, P.; Suzuki, R.; Mizobuchi, S.; Yamaguchi, T.; Sasaguri, S. Bilirubin exhibits a novel anti-cancer effect on human adenocarcinoma. *Biochem. Biophys. Res. Commun.* 2006, 342, 1279–1283. [CrossRef]

39. Tukey, R.H.; Strassburg, C.P. Human UDP-glucuronosyltransferases: Metabolism, expression, and disease. *Annu. Rev. Pharmacol. Toxicol.* 2000, 40, 581–616. [CrossRef] [PubMed]

40. Carr, B.I.; Guerra, V.; Giannini, E.G.; Farinati, F.; Ludovico Rapaccini, G.; Di Marco, M.; Benvegnù, L.; Zoli, M.; Borzio, F.; et al. Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype. *Semin. Oncol.* 2014, 41, 252–258. [CrossRef]

41. Erlinger, S.; Arias, I.M.; Dhumeaux, D. Inherited disorders of bilirubin transport and conjugation: New insights into molecular mechanisms and consequences. *Gastroenterology* 2014, 146, 1625–1638. [CrossRef] [PubMed]

42. Tripathi, N.; Jialal, I. *Conjugated Hyperbilirubinemia*; StatPearls Publishing: Treasure Island, FL, USA, 2020.

43. Wu, Z.; Han, M.; Chen, T.; Yan, W.; Ning, Q. Acute liver failure: Mechanisms of immune-mediated liver injury. *Liver Int.* 2010, 30, 782–794. [CrossRef]

44. Ioannou, G.N.; Liou, I.W.; Weiss, N.S. Serum bilirubin and colorectal cancer risk: A population-based cohort study. *Aliment. Pharmacol. Ther.* 2006, 23, 1637–1642. [CrossRef]

45. Zucker, S.D.; Horn, P.S.; Sherman, K.E. Serum bilirubin levels in the U.S. population: Gender effect and inverse correlation with colorectal cancer. *Hepatology* 2004, 40, 827–835. [CrossRef]

46. Muraca, M.; Favery, J. Influence of sex and sex steroids on bilirubin uridine diphosphate-glucuronosyltransferase activity of rat liver. *Gastroenterology* 1984, 87, 308–313. [CrossRef]

47. Buckley, D.B.; Klaassen, C.D. Mechanism of gender-divergent UDP-glucuronosyltransferase mRNA expression in mouse liver and kidney. *Drug Metab. Dispos.* 2009, 37, 834–840. [CrossRef] [PubMed]

48. Seyed Khoei, N.; Carreras-Torres, R.; Murphy, N.; Gunter, M.J.; Brennan, P.; Smith-Byrne, K.; Mariosa, D.; Mckay, J.; O’Mara, T.A.; Jarrett, R.; et al. Genetically Raised Circulating Bilirubin Levels and Risk of Ten Cancers: A Mendelian Randomization Study. *Cells* 2021, 10, 394. [CrossRef]